ストックスクリーナーアプリを入手
68.25
0.23%
0.16
プレマーケット:
68.27
0.02
+0.03%
前日終値:
$68.09
開ける：
$67.81
24時間の取引高:
565.82K
Relative Volume:
0.85
時価総額：
$2.88B
収益：
$17.39M
当期純損益:
$-135.89M
株価収益率:
-14.71
EPS:
-4.64
ネットキャッシュフロー:
$-123.00M
1週間 パフォーマンス:
-0.81%
1か月 パフォーマンス:
-0.25%
6か月 パフォーマンス:
+44.14%
1年 パフォーマンス:
+45.86%
1日の値動き範囲:
$65.93
$69.25
1週間の範囲:
$65.93
$71.95
52週間の値動き範囲:
$38.51
$76.81
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
名前
Tarsus Pharmaceuticals Inc
セクター
電話
(949) 409-9820
住所
15440 LAGUNA CANYON ROAD, IRVINE
TARS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
68.25 | 2.89B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-27 | 再開されました | H.C. Wainwright | Buy |
| 2023-11-20 | 開始されました | Goldman | Neutral |
| 2023-07-18 | 開始されました | William Blair | Outperform |
| 2023-05-18 | 開始されました | Guggenheim | Buy |
| 2022-08-01 | 開始されました | Barclays | Overweight |
| 2021-12-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-23 | 開始されました | Oppenheimer | Outperform |
| 2020-11-10 | 開始されました | BofA Securities | Buy |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-11-10 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Tarsus Pharmaceuticals Inc (TARS) 最新ニュース
What catalysts could drive Tarsus Pharmaceuticals Inc. stock higher2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
Long term hold vs stop loss in Tarsus Pharmaceuticals Inc.July 2025 Sector Moves & Fast Entry and Exit Trade Plans - newser.com
(TARS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
What momentum indicators show for Tarsus Pharmaceuticals Inc. stockJuly 2025 Rallies & Verified Momentum Stock Ideas - newser.com
Can Tarsus Pharmaceuticals Inc. recover in the next quarterWeekly Profit Recap & AI Driven Price Predictions - newser.com
Is Tarsus Pharmaceuticals Inc. stock poised for growthIndex Update & Reliable Intraday Trade Plans - newser.com
Forecasting Tarsus Pharmaceuticals Inc. price range with options dataQuarterly Earnings Summary & Intraday High Probability Setup Alerts - newser.com
Will Tarsus Pharmaceuticals Inc. stock deliver shareholder value2025 Technical Overview & Weekly High Return Stock Forecasts - newser.com
Tarsus outlines $140M–$145M Q4 sales target while expanding XDEMVY adoption and pipeline progress - MSN
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2025 Earnings Call Transcript - Insider Monkey
Is Tarsus Pharmaceuticals Inc. showing signs of accumulationQuarterly Profit Summary & AI Enhanced Trade Execution Alerts - newser.com
What to expect from Tarsus Pharmaceuticals Inc. in the next 30 daysMarket Performance Recap & Stock Portfolio Risk Management - newser.com
Can Tarsus Pharmaceuticals Inc. stock sustain market leadership2025 Buyback Activity & Consistent Profit Focused Trading Strategies - newser.com
Is Tarsus Pharmaceuticals Inc. stock a safe investment in uncertain markets - newser.com
Tarsus Pharmaceuticals (TARS): Losses Widen Despite Strong Growth Outlook, Challenging Bullish Narratives - Yahoo Finance
Is Tarsus Pharmaceuticals Inc. stock cheap at current valuation2025 Market Overview & Technical Confirmation Alerts - newser.com
Is Tarsus Pharmaceuticals Inc. stock in correction or buying zonePortfolio Performance Report & Low Drawdown Momentum Ideas - fcp.pa.gov.br
Tarsus to Participate in Upcoming Investor Conference - Sahm
Does Tarsus Pharmaceuticals Inc. fit your quant trading modelQuarterly Profit Summary & Expert Verified Movement Alerts - newser.com
How analysts rate Tarsus Pharmaceuticals Inc. stock todayWeekly Profit Recap & Free Safe Entry Trade Signal Reports - newser.com
Top chart patterns to watch in Tarsus Pharmaceuticals Inc.Market Risk Analysis & Weekly Watchlist of Top Performers - newser.com
Tarsus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Quarterly Earnings Results - MarketBeat
Tarsus (NASDAQ: TARS) plans fireside chat Nov. 11, 2:30 p.m. ET at Guggenheim conference - Stock Titan
Guggenheim Maintains Buy Rating for TARS, Raises Target to $87 | - GuruFocus
Can Tarsus Pharmaceuticals Inc. stock resist market sell offsTake Profit & Risk Adjusted Buy and Sell Alerts - newser.com
Full technical analysis of Tarsus Pharmaceuticals Inc. stockWeekly Market Report & Weekly High Conviction Trade Ideas - newser.com
What’s the recovery path for long term holders of Tarsus Pharmaceuticals Inc.Quarterly Profit Summary & Reliable Intraday Trade Alerts - newser.com
Decoding Tarsus Pharmaceuticals Inc (TARS): A Strategic SWOT Ins - GuruFocus
Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
Tarsus Pharmaceuticals Reports Strong Q3 2025 Growth - TipRanks
Transcript : Tarsus Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 04, 2025 - MarketScreener
Tarsus Pharmaceuticals Outpaces Expectations On XDEMVY Sales Growth - Finimize
Earnings call transcript: Tarsus Pharmaceuticals beats Q3 2025 expectations By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Earnings call transcript: Tarsus Pharmaceuticals beats Q3 2025 expectations - Investing.com
Tarsus Pharma Q3 revenue beats estimates, driven by XDEMVY sales - MarketScreener
Earnings Flash (TARS) Tarsus Pharmaceuticals, Inc. Reports Q3 Revenue $118.7M, vs. FactSet Est of $115.2M - MarketScreener
Tarsus Pharmaceuticals (TARS) Q3 2025 Earnings: EPS of $(0.30) B - GuruFocus
TARS Reports Strong Q3 Revenue Boosted by XDEMVY Sales - GuruFocus
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements - The Manila Times
Tarsus Pharmaceuticals Reports Q3 2025 Financial Results with XDEMVY® Sales Surging to $119 Million, Up 147% Year-Over-Year - Quiver Quantitative
Tarsus Pharmaceuticals Inc (TARS) 財務データ
収益
当期純利益
現金流量
EPS
5.44%
0.70%
大文字化:
|
ボリューム (24 時間):